Genmab A/S Files 6-K, Incorporates by Reference
Ticker: GNMSF · Form: 6-K · Filed: Dec 12, 2025 · CIK: 1434265
| Field | Detail |
|---|---|
| Company | Genmab A/S (GNMSF) |
| Form Type | 6-K |
| Filed Date | Dec 12, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, regulatory, announcement
TL;DR
Genmab filed a 6-K on 12/12/25, incorporating announcements into existing S-8 filings.
AI Summary
Genmab A/S filed a Form 6-K on December 12, 2025, to report company announcements. This filing is incorporated by reference into several of Genmab's existing Form S-8 registration statements, including File Nos. 333-232693, 333-253519, 333-262970, 333-277273, and 333-284876.
Why It Matters
This filing ensures that important company announcements are officially registered with the SEC and become part of Genmab's public record, potentially impacting investor awareness and regulatory compliance.
Risk Assessment
Risk Level: low — This is a routine filing that incorporates previous announcements and does not appear to contain new material financial or operational information.
Key Players & Entities
- Genmab A/S (company) — Registrant
- 333-232693 (dollar_amount) — Form S-8 File Number
- 333-253519 (dollar_amount) — Form S-8 File Number
- 333-262970 (dollar_amount) — Form S-8 File Number
- 333-277273 (dollar_amount) — Form S-8 File Number
- 333-284876 (dollar_amount) — Form S-8 File Number
- December 12, 2025 (date) — Filing Date
FAQ
What is the purpose of this Form 6-K filing by Genmab A/S?
The purpose of this Form 6-K filing is to report company announcements and to be incorporated by reference into Genmab A/S's existing registration statements on Form S-8.
When was this Form 6-K filed?
This Form 6-K was filed on December 12, 2025.
Which registration statements does this 6-K filing get incorporated into?
This 6-K filing is incorporated by reference into Genmab A/S's registration statements on Form S-8 with File Numbers 333-232693, 333-253519, 333-262970, 333-277273, and 333-284876.
What is the primary exhibit included in this filing?
The primary exhibit included in this filing is Exhibit 99.1, which is a Company Announcement dated December 12, 2025.
What is Genmab A/S's principal executive office address?
Genmab A/S's principal executive office is located at Carl Jacobsens Vej 30, 2500 Valby, Denmark.
Filing Stats: 214 words · 1 min read · ~1 pages · Grade level 14.4 · Accepted 2025-12-12 07:00:08
Filing Documents
- gmab_20251212x6k.htm (6-K) — 13KB
- gmab_20251212xex991.htm (EX-99.1) — 22KB
- genmab_logo.jpg (GRAPHIC) — 56KB
- 0001434265-25-000110.txt ( ) — 110KB
From the Filing
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF DECEMBER 2025 COMMISSION FILE NUMBER 001-38976 Genmab AS (Exact name of Registrant as specified in its charter) Carl Jacobsens Vej 30 2500 Valby Denmark +45 70 20 27 28 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F This report on Form 6-K shall be deemed to be incorporated by reference in Genmab AS's registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970, 333-277273 and 333-284876 ) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. EXHIBIT INDEX Exhibit Description of Exhibit 99.1 Company Announcement Dated December 12, 2025 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. GENMAB AS BY s Anthony Pagano Name Anthony Pagano Title Executive Vice President Chief Financial Officer DATE December 12, 2025